SCHEMBL2349591

SCHEMBL2349591

Oc1nccc(-c2ccc(F)cc2)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.66
KMT2A Q03164 7/20 0.66
NPC1 O15118 3/20 0.66
RAB9A P51151 2/20 0.66
ATM Q13315 1/20 0.66
MAPT P10636 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 1/20 0.46
TRPV3 Q8NET8 1/20 0.44
PIK3CA P42336 2/20 0.42
PIK3CG P48736 2/20 0.42
PIK3CB P42338 1/20 0.42
AURKA O14965 1/20 0.41
HSP90AA1 P07900 1/20 0.41
PRKACA P17612 1/20 0.41
ADORA2A P29274 1/20 0.41
TDO2 P48775 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ALOX5 P09917 1/20 0.40
ALK Q9UM73 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17200126 0.80 HSP90AA1 (0.66) MEN1KMT2ANPC1RAB9AATM
SCHEMBL592929 0.79 ADORA2A (0.64) MEN1KMT2ANPC1RAB9AATM
SCHEMBL2349687 0.78 KMO (0.63) MEN1KMT2ANPC1RAB9AATM
SCHEMBL446173 0.78 MEN1 (0.58) MEN1KMT2ANPC1RAB9AATM
SCHEMBL2404944 0.76 KDM4E (0.59) MEN1KMT2ANPC1RAB9AATM
SCHEMBL2115251 0.76 CAMK2D (0.57) MEN1KMT2ANPC1RAB9AGAA
SCHEMBL28135243 0.73 KMT2A (0.72) MEN1KMT2ANPC1RAB9AATM
SCHEMBL28135323 0.73 KMT2A (0.72) MEN1KMT2ANPC1RAB9AATM
Bicarbonate SCHEMBL28044676 0.73 KMT2A (0.71) MEN1KMT2ANPC1RAB9AATM
SCHEMBL27157236 0.72 NPC1 (0.56) MEN1KMT2ANPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008488-B2 Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2011-08-30 US disclosed
EP-1601659-B1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO KG (DE) 2008-01-16 EP disclosed
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ABBOT GMBH & CO. KG (DE) 2006-10-19 US disclosed
EP-1601659-A1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS Abbott GmbH & Co. KG (DE) 2005-12-07 EP disclosed
WO-2004080981-A1 PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS ABBOTT GMBH & CO. KG (DE) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ADRB3, DRD3, OPRL1 MEN1 4488/4885KMT2A 4190/4885NPC1 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.